Literature DB >> 33459264

Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.

Liang Zhao1, Hongyao Du1, Mahin Alamgir2, Jing Yang1, Xiaoping Miao3, Biling Jiang1, Yuting Xia1, Yuchen Lou1, Yujue Wang1, Chen Shen1, Jinjin Zhu1, Wen-Hung Chung4, Yan Li1, Juan Tao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33459264      PMCID： PMC7880659          DOI： 10.1684/ejd.2020.3908

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  8 in total

Review 1.  Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Silvia Minozzi; Stefanos Bonovas; Theodore Lytras; Valentina Pecoraro; Marien González-Lorenzo; Anan Judina Bastiampillai; Eugenia Maria Gabrielli; Andrea Carlo Lonati; Lorenzo Moja; Michela Cinquini; Valentina Marino; Andrea Matucci; Giuseppe Maria Milano; Giuliano Tocci; Raffaele Scarpa; Delia Goletti; Fabrizio Cantini
Journal:  Expert Opin Drug Saf       Date:  2016-12       Impact factor: 4.250

2.  BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14.

Authors:  Ye Tian; Chongmin Jiang; Mei Wang; Rui Cai; Yanfeng Zhang; Zihong He; Huan Wang; Dongming Wu; Fubaihui Wang; Xin Liu; Zhongtao He; Ping An; Munan Wang; Qiang Tang; Yang Yang; Jin Zhao; Shaojun Lv; Weihai Zhou; Bo Yu; Jiang Lan; Xinping Yang; Linxia Zhang; Hui Tian; Zhuangzhuang Gu; Yiqing Song; Tianyi Huang; Lars R McNaughton
Journal:  Lancet Diabetes Endocrinol       Date:  2016-04-28       Impact factor: 32.069

Review 3.  Psoriasis pathogenesis and the development of novel targeted immune therapies.

Authors:  Jason E Hawkes; Tom C Chan; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2017-09       Impact factor: 10.793

Review 4.  Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.

Authors:  Jason E Hawkes; Bernice Y Yan; Tom C Chan; James G Krueger
Journal:  J Immunol       Date:  2018-09-15       Impact factor: 5.422

5.  Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.

Authors:  Erica D Dommasch; Seoyoung C Kim; Moa P Lee; Joshua J Gagne
Journal:  JAMA Dermatol       Date:  2019-10-01       Impact factor: 10.282

6.  Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.

Authors:  Paolo Gisondi; Gianluigi Zaza; Micol Del Giglio; Mattia Rossi; Valentina Iacono; Giampiero Girolomoni
Journal:  J Am Acad Dermatol       Date:  2020-04-21       Impact factor: 11.527

7.  Should biologics for psoriasis be interrupted in the era of COVID-19?

Authors:  Mark Lebwohl; Ryan Rivera-Oyola; Dedee F Murrell
Journal:  J Am Acad Dermatol       Date:  2020-03-19       Impact factor: 11.527

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321
  8 in total
  1 in total

Review 1.  Biologics for Psoriasis During the COVID-19 Pandemic.

Authors:  Huanhuan Zeng; Siyu Wang; Ling Chen; Zhu Shen
Journal:  Front Med (Lausanne)       Date:  2021-12-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.